UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
FDA begins to review Samsung Bioepis' anticancer biosimilar application
Samsung Bioepis headquarters in Songdo, Incheon. Samsung Bioepis said tha...
by Lee Han-soo
|
2019-11-20 15:10
라인
Vivozon’s acquisition of Lumimicro may aim at backdoor listing
Vivozon, a privately held biopharmaceutical firm on the over-the-counter (O...
by Jeong Sae-im
|
2019-11-20 14:44
라인
ABL Bio, Genscript to cooperate on bispecific antibodies
ABL Bio said that it would co-develop new bispecific antibodies with Genscr...
by Lee Han-soo
|
2019-11-19 17:18
라인
Will Biogen be 1st to get FDA nod for Alzheimer’s drug?
Biogen recently unveiled the new results of studies on aducanumab, an inves...
by Kim Yun-mi
|
2019-11-14 11:23
라인
How can Korean drugmakers enter Europe successfully?
Officials from the Korea Pharmaceutical and Bio-Pharma Manufacturers Associ...
by Jeong Sae-im
|
2019-11-13 15:22
라인
Samsung Bioepis expects ₩1 trillion biosimilar sales this year
Samsung Bioepis said it was confident of achieving 1 trillion won ($855.8 m...
by Jeong Sae-im
|
2019-11-13 15:21
라인
[News Focus] ‘FDA could allow resumption of Invossa trial’
Amid the prosecution’s probe into Kolon Life Science’s osteoarthritis gene ...
by Jeong Sae-im
|
2019-11-12 15:48
라인
Celltrion marks robust Q3 sales
Celltrion said that it has recorded sales of 289.1 billion won ($249 millio...
by Lee Han-soo
|
2019-11-07 14:03
라인
Samsung Bioepis, Biogen to commercialize next-generation biosimilar candidates
Samsung Bioepis said the company would strengthen its partnership with Biog...
by Lee Han-soo
|
2019-11-07 11:16
라인
Court rejects arrest warrant for 2 Kolon execs
A local court has refused to issue an arrest warrant against two executives...
by Jeong Sae-im
|
2019-11-05 13:54
라인
Samsung BioLogics to make Ichnos Sciences’ atopic dermatitis treatment
Samsung Biologics said that it has signed a contract with Ichnos Sciences t...
by Lee Han-soo
|
2019-11-05 12:47
라인
Prosecutors seek to arrest 2 Kolon execs for false Invossa data
Prosecutors have sought arrest warrant for two executives of Kolon Life Sci...
by Jeong Sae-im
|
2019-10-31 15:34
라인
Syntekabio passes prior review for Kosdaq listing
Syntekabio, a new drug developer using artificial intelligence (AI)-based g...
by Jeong Sae-im
|
2019-10-31 13:27
라인
Prosecution seeks jail term for Samsung execs for destroying evidence
Prosecutors demanded jail terms of one to four years for Samsung executives...
by Jeong Sae-im
|
2019-10-29 13:10
라인
KangStem Biotech changes strategy for atopic dermatitis drug
KangStem Biotech changed its strategy for Furestem-AD, an investigational s...
by Jeong Sae-im
|
2019-10-28 15:34
라인
Bridge Biotherapeutics passes preliminary review for Kosdaq listing
Bridge Biotherapeutics has passed the regulatory agency’s preliminary revie...
by Jeong Sae-im
|
2019-10-25 15:05
라인
Celltrion launches Herzuma in Brazil
Celltrion Healthcare said that it has launched its anticancer antibody bios...
by Lee Han-soo
|
2019-10-25 13:56
라인
KangStem Biotech fails in phase-3 study on atopic dermatitis drug
KangStem Biotech said it has failed to prove the efficacy of Furestem-AD, a...
by Jeong Sae-im
|
2019-10-25 11:17
라인
Samsung Bioepis' biosimilar sales in EU top $180 million in Q3
Samsung Bioepis' biosimilar sales in European Union surpassed $180 mill...
by Lee Han-soo
|
2019-10-23 17:43
라인
Medipost wins patent for mesenchymal stem cell culture in China
Medipost said that it has registered a patent for cultivating mesenchymal s...
by Lee Han-soo
|
2019-10-23 16:30
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top